🧠Advancing a New Therapeutic Candidate for Parkinson’s Disease
Reference: SIID – MPr-2025-4 / CENTRO2030-FEDER-02960700
NeuroSoV has been awarded a new R&D co-promotion grant under the PT2030 Programme to advance the CogniPD+ project — a preclinical initiative focused on validating an innovative therapeutic candidate for Parkinson’s Disease.
Developed in collaboration with the University of Beira Interior (https://www.ubi.pt) and other scientific partners, CogniPD+ builds upon the company’s patented ionic-liquid formulation targeting NOX1/NOX4 enzymes — key drivers of oxidative stress and neurodegeneration in Parkinson’s Disease.
The project will conduct advanced pharmacokinetic (DMPK) and efficacy studies, develop a new translational animal model, and prepare the transition to GLP safety studies required for regulatory submission. By bridging preclinical validation and clinical readiness, CogniPD+ represents a decisive step towards delivering a first-in-class disease-modifying therapy for patients living with Parkinson’s Disease.
🧠Avançar um Novo Candidato Terapêutico para a Doença de Parkinson
Referência: SIID – MPr-2025-4 / CENTRO2030-FEDER-02960700
A NeuroSoV obteve um novo financiamento no âmbito do programa PT2030 para o projeto CogniPD+, desenvolvido em copromoção com a Universidade da Beira Interior (https://www.ubi.pt) e outros parceiros cientĂficos.
O CogniPD+ visa validar, em fase prĂ©-clĂnica, um candidato terapĂŞutico inovador baseado numa formulação patenteada em lĂquido iĂłnico que inibe seletivamente as enzimas NOX1/NOX4 — alvos centrais no stress oxidativo e na neurodegeneração associada Ă Doença de Parkinson.
O projeto inclui estudos avançados de farmacocinĂ©tica e eficácia, o desenvolvimento de um novo modelo animal translacional e a preparação para os ensaios de segurança em conformidade com as Boas Práticas Laboratoriais (GLP). Este marco reforça a missĂŁo da NeuroSoV em transformar inovação cientĂfica em terapias modificadoras da doença, aproximando soluções eficazes dos doentes com Parkinson.
NeuroSoV received the Women Tech EU grant award!
Funded under the European Innovation Ecosystems work programme of Horizon Europe, Women TechEU is a initiative of the European Union. The scheme offers first-class coaching and mentoring to female founders, as well as targeted funding to help take their businesses to the next level.
NeuroSoV/Fastprinciple is one of the awardees of the 2022 award edition!
New therapeutic approach to slowdown the progression of Parkinson’s disease
Reference: SI-47-2020-13/CENTRO-01-0247-FEDER-113213
NeuroSoV has won a grant for research and development in co-promotion from the Portuguese Government on April 2021. Such project involves 2 Portuguese Universities, University of Beira Interior (https://www.ubi.pt) and University of Aveiro (https://www.ua.pt), NeuroSoV and ih-Care (https://www.ihcare.pt/. Patients and society expect that technical and scientific advances can provide novel improved answers to address unmet medical needs. The absence of preventive therapies that interrupt the progression of PD requires the development of new therapeutic strategies. The oxidative stress process contributes for the progression of PD pathogenesis, being an ideal therapeutic target. Herein, we will test a chemical inhibitor that exhibited an exceptional neuroprotective effect in PD models. This project aims to prove the pharmacological efficacy and therapeutic application for PD of the reformulated inhibitor.
Ficha TĂ©cnica: https://www.dropbox.com/s/tly5ap5sg6lqkwv/Ficha%20Tecnica_PDSolve.tiff?dl=0
NeuroSoV at Websummit
NeuroSoV was live at the 2020 Websummit event, as invited speaker at the Masterclass Healthtech Lisboa: a new venture builder.
Startup Olé
Won in the vertical University Pavilion STARTUP OLÉ 2020 DIGITAL EDITION PITCH COMPETITION #startupole organized by Startup OLÉ Accelerator.
New Experimental Model for PD research
NeuroSoV new scientific paper characterizing an Improved paraquat (PQ)-based rat model that recapitulates cardinal features of PD pathology. The new low dose of PQ exposure paradigm using osmotic minipumps, generated a rodent model of PD that reproduces increases of the nigrostriatal dopaminergic lesion, sustained neuroinflammation, oxidative stress and a-synuclein pathology overtime, complemented with the motor deficit. DOI: 10.1111/ejn.14683
Â
[/vc_column_text][/vc_column][/vc_row]